Otezla (apremilast) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:	MEMBER'S FIRST NAME:	
	e.g., chart notes or lab dat	mpletely and legibly. Attach any additional docu a, to support the authorization request). Inform AA.		
			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:	STATE: ZIP CODE:	
PATIENT INSURANCE ID I	NUMBER:	l		
IF YOU ARE NOT THE PATIENT OR THE PR FOLLOWING LINK: PRIMETHERAPEUTICS.	ESCRIBER, YOU WILL NEED TO SUBMIT A COM/NOPP	WEIGHT (LB/KG): ALLERGIES:	AN BE FOUND AT THE	
		CABLE):		
PRESCRIBER INFORMATION	ON			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	OFFICE CONTACT PERSON:	
MEDICATION OR MEDICA	AL DISPENSING INFORMA	ATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF QUANT THERAPY/REFILLS:	ITY:	
NEW THERAPY DURATION OF THERAPY (RENEWAL SPECIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATE	D:	

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company



Continued on next page

Revision Date: 8/15/24

Otezla (apremilast) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Plaque psoriasis □ Psoriatic arthritis □ Recurrent ulcers due to Behcet's diseas □ Other diagnosis:ICI		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Clinical information:	patient as part of a treatment regimen s	pecified within a sponsored clinical
Does patient have less than 3% of BSA contraction that causes disruption of normal activities	s □ No 6 or more of their body surface area (BSA)? overed with plaques, but has involvement o	f palms, soles, head and neck, or genitalia
leflunamide(Arava), and/or acitretin Does patient have a contraindication documentation/rationale.		:hotrexate? □ Yes □ No <i>Please submit</i>
Renewal Request:		
Is patient continuing to demonstrate	e a positive clinical response? Yes No	o Please submit documentation.
Will patient use requested medication immunomodulatory agent? ☐ Yes ☐	on in combination with another biologic No	response modifier or
For recurrent ulcers due to Behcet's	disease, answer the following:	
Has patient had active ulcers at least	three times in the past 12 months? \Box)	es \square No <i>Please submit documentation</i> .
Is patient positive for at least 2 of the	e following four findings? ☐ Yes ☐ No	Please submit documentation.
☐ Genital ulcerations in the form of	active genital lesions and/or genital scars	
☐ Skin lesions in the form of erythen	na nodosum, folliculitis or other non-genital	ulcerations
□ Eve involvement in the form of an	terior uveitis nosterior uveitis cells in vitre	ous on slit-lamp examination and/or



Otezla (apremilast) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
retinal vasculitis	
 Postive pathergy test, as demonstrated by 	y the formation of a sterile pustule 24-48hrs after pinprick
1	nbiologic therapy for oral ulcers (such as topical glucocorticoids, e or immunosuppressants)? Yes No Please submit documentation
Are there any other comments, diagnoses, s physician feels is important to this review?	symptoms, medications tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are cover information is received.	ered on all plans. This request may be denied unless all required
· ·	ided is true and accurate to the best of my knowledge. I understand that s designees may perform a routine audit and request the medical of the information reported on this form.
Prescriber Signature or Electronic I.D. Verific	cation: Date:
you are not the intended recipient, you are hereby not	ying this transmission contain confidential health information that is legally privileged. If tified that any disclosure, copying, distribution, or action taken in reliance on the contents eceived this information in error, please notify the sender immediately (via return FAX) uments.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811

St. Paul, MN 55164-0811

